AtaiBeckley (FRA:B72) Other Current Receivables: €11.38 Mil (As of Mar. 2026)


FRA:B72 AtaiBeckley Inc FRA:B72
53 GF Score
Price €4.10
GF Value €5.61
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is AtaiBeckley Other Current Receivables?

AtaiBeckley FRA:B72 -5.53% 53 Other Current Receivables is €11.38 Mil as of Mar. 2026. GuruFocus rates FRA:B72 with a GF Score™ of 53/100 and a GF Value™ of €5.61 (Modestly Undervalued). The stock has 6 warning signs investors should review.

AtaiBeckley's Other Current Receivables for the quarter that ended in Mar. 2026 was €11.38 Mil.

AtaiBeckley's quarterly Other Current Receivables increased from Sep. 2025 (€0.77 Mil) to Dec. 2025 (€11.22 Mil) and increased from Dec. 2025 (€11.22 Mil) to Mar. 2026 (€11.38 Mil).

AtaiBeckley's annual Other Current Receivables declined from Dec. 2023 (€1.61 Mil) to Dec. 2024 (€1.29 Mil) but then increased from Dec. 2024 (€1.29 Mil) to Dec. 2025 (€11.22 Mil).

AtaiBeckley Other Current Receivables Related Terms

AtaiBeckley Other Current Receivables Historical Data

* Premium members only.

The historical data trend for AtaiBeckley's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtaiBeckley Other Current Receivables Chart

AtaiBeckley Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 4.78 5.32 1.61 1.29 11.22

AtaiBeckley Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.38 1.13 0.77 11.22 11.38
FRA:B72
53GF Score
AtaiBeckley Inc FRA:B72
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AtaiBeckley Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €11.38 Mil mean?
AtaiBeckley (FRA:B72) has a Other Current Receivables of €11.38 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on AtaiBeckley and its competitors.
Is AtaiBeckley's Other Current Receivables too high?
AtaiBeckley's current Other Current Receivables is €11.38 Mil. Overall, AtaiBeckley has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtaiBeckley's Other Current Receivables compare to GHRS and NUVB?
AtaiBeckley's Other Current Receivables of €11.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on AtaiBeckley and its competitors. AtaiBeckley's current Other Current Receivables is €11.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtaiBeckley stock overvalued right now?
Based on GuruFocus' analysis, AtaiBeckley (FRA:B72) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.61, compared to a current price of €4.10 — trading 26.9% below its estimated fair value. The current Other Current Receivables is €11.38 Mil. AtaiBeckley's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For AtaiBeckley (FRA:B72), the current Other Current Receivables is €11.38 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AtaiBeckley (FRA:B72) Overvalued in 2026?

Based on GuruFocus' analysis, AtaiBeckley stock appears to be undervalued. The current stock price of €4.10 is trading 26.9% below its estimated GF Value™ of €5.61. GuruFocus considers AtaiBeckley to be Modestly Undervalued.

Key valuation signals for FRA:B72:

  • Other Current Receivables: €11.38 Mil
  • GF Value™: €5.61 vs. price of €4.10 (26.9% below fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the FRA:B72 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AtaiBeckley Business Description

Other Exchanges ATAI:USAB72:Germany
Address 250 West 34th Street, New York, NY, USA, 10119
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
53GF Score

Get the complete analysis for FRA:B72

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.10
Price
€5.61
GF Value